Verastem Oncology: When Your Earnings Call Gets More Attention Than Your Pipeline Ever Did

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Verastem typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows significant volatility around Verastem earnings releases, with Day +1 moves averaging 7.67% in absolute terms and ranging as high as 19.93%. The most recent earnings release (May 7, 2026) triggered a 13.60% decline on Day +1 despite the company meeting EPS expectations, suggesting investors were disappointed by other aspects of the report—likely revenue or guidance. Prior to that, March 2026 earnings produced a 5.85% gain, while November 2025 saw a dramatic 20.10% decline on Day 0 (likely reflecting after-hours reaction to the significant earnings miss that quarter).

The average Day +1 range of 11.96% indicates substantial intraday volatility as the market digests results and management commentary. Notably, August 2025 earnings delivered a 19.93% surge on Day +1, demonstrating the stock's potential for explosive moves when results exceed expectations. The pattern suggests VSTM is a high-beta earnings play where execution matters significantly—beats can drive double-digit gains while misses or disappointing guidance can trigger similar-magnitude declines. Investors should prepare for meaningful price movement regardless of direction.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.38% (±$1.02) for the August 21 expiration, which is significantly higher than the historical average Day +1 move of 7.67% but well within the historical range given the stock's 19.93% surge in August 2025 and 13.60% decline in May 2026. The elevated implied volatility of 190.61% suggests options traders are anticipating above-average volatility for this release, likely reflecting uncertainty around commercial momentum and pipeline updates.

Part 3: What Analysts Are Saying

Analysts maintain a Strong Buy consensus on Verastem with an average price target of $15.00, implying 155% upside from the current price of $5.87. The rating breakdown shows 7 Strong Buys, 1 Moderate Buy, and 1 Hold, with no sell ratings—a decidedly bullish stance. The average recommendation score of 4.67 out of 5.00 reflects near-unanimous optimism about the company's prospects.

Price targets range from a low of $8.00 to a high of $18.00, with even the most conservative target implying 36% upside from current levels. The analyst count has remained stable at 9 total recommendations over the past month, and sentiment is classified as unchanged, indicating the bullish thesis has held steady despite recent stock price volatility.

The Strong Buy consensus appears driven by several factors evident in analyst commentary: the COPIKTRA commercial ramp is gaining traction with over 400 prescribers and a clear path to self-sustainability in H2 2026; the VS-7375 pipeline offers multiple shots on goal with three registration-directed trials launching in high-value oncology indications; and the company's cash position provides adequate runway to reach key value-inflection points. The lack of sell ratings and concentration of Strong Buy recommendations suggests analysts view current levels as an attractive entry point ahead of potential catalysts from both commercial execution and clinical data readouts.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 8%, unchanged from last week's Buy at 8% but representing a significant reversal from last month's Sell at 56%. This dramatic shift from bearish to bullish over the past month suggests technical momentum has stabilized following earlier weakness.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive, though not at extreme levels
• Medium-term (50% Sell): Conflicting sell signal suggests intermediate-term trend remains under pressure despite recent improvement
• Long-term (Hold): Neutral reading reflects an absence of clear directional bias in the longer-term trend structure

Trend Characteristics: The combination of Minimum strength and Average direction suggests the stock is in a transitional phase with modest momentum but no decisive trend establishment—a setup that leaves the stock vulnerable to significant post-earnings volatility in either direction.

The stock is currently trading at $5.87, positioned above its 5-day moving average of $5.85, below its 10-day moving average of $5.98, above its 20-day moving average of $5.84, above its 50-day moving average of $4.78, above its 100-day moving average of $5.10, and below its 200-day moving average of $6.39. This mixed picture shows the stock has recovered from its 50-day and 100-day lows but remains in a downtrend relative to its 200-day average.

The technical setup heading into earnings is neutral to cautiously constructive. The stock has established support above the $4.78 level (50-day MA) and is trading in a tight range between the 20-day ($5.84) and 10-day ($5.98) moving averages, suggesting consolidation ahead of the catalyst. However, the failure to reclaim the 200-day moving average at $6.39 indicates longer-term resistance remains overhead. The conflicting timeframe signals—short-term buy versus medium-term sell—create a setup where earnings results and guidance will likely determine whether the stock breaks out above the $6.00 level or retreats toward the $4.78-$5.00 support zone. Given the options market's expectation of a 17.38% move and historical precedent for double-digit swings, traders should expect the technical picture to shift dramatically based on execution and forward guidance.